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OXIDATIVE STRESS IN STABLE CF PATIENTS: DO WE NEED HIGHER 
ANTIOXIDANT PLASMA LEVELS? 
ABSTRACT 
Oxidative stress plays an important role in cystic fibrosis (CF). However, there is a lack of validated 
biomarkers of oxidative damage that correlate with the antioxidant needs of patients with CF'. 
Objective: to investigate oxidative stress in stable pediatric CF patients and evaluate if vitamin 
supplementation may be tailored on individual needs and oxidative status. 
Results: Lipid-adducts 4-hydroxynonenal (HNE-L) and malonaldehyde (MDA-L) (chromolipids) were 
elevated in the majority of patients despite normal pl sma vitamin E, A and C. HNE-L and MDA-L 
increased with age, while plasma vitamins decreased. The most relevant correlation was identified between 
vitamin C and chromolipids. Patients with pancreatic insufficiency (PI) showed significantly higher plasma  
chromolipids despite no differences in plasma vitamns.   
Conclusions: The majority of patients showed elevated plasma chromolipids that increased with age. 
Antioxidant vitamins reference ranges provide incomplete information on the redox status. CF patients 
with PI showed excessive oxidative stress damage. 
INTRODUCTION 
Cystic fibrosis (CF) is characterized by elevated oxidative stress and impaired 
antioxidant/oxidant balance (1). Chronic infection a d inflammation increase the free radical 
production. This could modulate the CFTR expression and function having a role in lung disease 
progression (2). At the same time, antioxidant defenses are dramatically reduced compared to 
healthy subjects (1,2,3), even early in the life (4).
Respiratory exacerbations lead to impairment of antioxidant defenses that restore after 
treatment (5). Increased number of exacerbations have been as well correlated to lower plasma 
vitamin E and A (6). Furthermore, markers of free radical damage have been demonstrated in 
plasma of CF patients despite the presence of normal concentrations of circulating antioxidants 
suggesting inadequate antioxidant defenses to cope with elevated oxidative stress with 
consequent progressive decline in pulmonary functio (4,7).  
An important feature in CF patients is the exocrine pancreatic insufficiency (PI), which 
causes maldigestion and malabsorption of liposoluble vitamins E and A. Unfortunately, 
pancreatic enzyme replacement therapy (PERT) does nt completely restore the absorption of 
these vitamins. Moreover, it has been demonstrated that vitamin deficiency can be independent 
of pancreatic function and PERT (8). Therefore, CF patients with PI need to receive daily 
vitamin supplements. The monitoring of plasma levels and supplementation of these vitamins is 
part of routine CF care (9,10). 
Normal ranges of plasma antioxidants correspond to those regarded as adequate for the non-
CF population i.e. healthy subjects. The optimal requirements for CF patients, based on 
antioxidant needs, may be higher than (these). Discussion on vitamin status has now shifted to 
the identification of optimal levels that provide btter health outcomes than suboptimal ones.  
Quantification of oxidative stress can be assessed by the detection of lipid peroxidation end-
products deriving from the degradation of polyunsaturated fatty acids, which are susceptible to 
oxidative attack by free radicals. Several markers fo  lipid peroxidation both in vitro and in vivo 
are available and different detection methods have be n described (11). Among these 
isoprostanes and aldehydes, such as MDA and HNE, are now the most studied products of lipid 
peroxidation involved in different respiratory pathologies (12,13). In particular, significantly 
elevated F2α-isoprostane have been found in breath condensate and pl sma of CF patients (2,14).  
Significantly elevated MDA in terms of thiobarbituric acid reactive substances 
(TBARS):cholesterol ratio, have been described to increase with age in CF patients (3). 
Compared to isoprostanes, the longer half-life of aldehydes makes them good candidates for 
propagation and amplification of effects elicited by free radicals. Among aldehydes, HNE is 
highly reactive with thiol- and amino-residues of proteins, peptides, lipids and nucleic acids (15).  
High MDA concentrations have been found to be negatively correlated with forced expiratory 
volume in 1 second (FEV1) in different airway diseas (2,3,16,17). Significant reduction and/or 
normalization of MDA plasma concentrations have been r ported after beta-carotene or 
multivitamin supplementation in CF patients (18,19). However, consideration should be given to 
the risk of toxicity and side-effects induced by the igh dose liposolubile vitamin supplementation. 
Although there is growing evidence of the potential role of oxidative reactions in the pathogenesis 
of CF, we still lack validated biomarkers of oxidative damage, which might serve to identify the 
effective amounts of antioxidants actually needed by CF patients.  
The present study was carried out to address this issue. The fluorimetric assay of aldehyde-
lipid adducts in plasma has been assessed exploiting the properties of MDA and HNE to be highly 
reactive forming stable adducts with functional groups of cell macromolecules (20). The aim was to 
identify the oxidative status in a group of stable CF patients in relation to their antioxidant and 
clinical status, in presence or absence of pancreati  insufficiency. These results may provide 
suitable “individual” reference ranges for a proper vitamin supplementation in CF patients.  
MATERIALS AND METHODS 
Patients’ recruitment 
We enrolled 70 subjects, 1 – 18 years old, progressiv ly attending the Pediatric Cystic Fibrosis 
Centre (Regina Margherita Hospital, Turin) from Janu ry 2007 to April 2008. All patients were in 
stable clinical conditions and were evaluated during the routine control visit. Our study included:  
Clinical data. Genotype, pancreatic insufficiency (fecal elastase < 200 µg/g), number of respiratory 
exacerbations during the last year.   
Anthropometric measurements. Body weight (kg, percentile, z-score), height/length (cm, 
percentile, z-score), Body Mass Index (kg/m2, percentile, z-score) calculated by Epi-Data Nut Stat 
(Epi Info 2000; developed by the CDC-Center for Disea e Control and Prevention-in Atlanta, 
Georgia; USA). 
Respiratory function test (RFT) was performed with a Bio Medine spirometer.  
 We calculated the mean value of the last year (for patients older than 6 years that were able to 
perform RFT) for FEV1 expressed as percentage of the predicted value for age and sex.  
Vitamin supplementation. Dosages of vitamins E and A and multivitamins were recorded. 
Nutritional evaluation . A three-days-food-record was analyzed to calculate the intake of energy, 
nutrients and antioxidants (software based analysis - Food Meter, Medimatica s.r.l., Martinsicuro, 
Teramo, Italy, 1990, modified by Turin University according to the Nutrition Tables of Italian 
National Institute of Nutrition).  Patients or parents were required to record prospectively the food 
consumed through three days. Food quantities were dscribed by using standard household 
measures (e.g. cups, tablespoons) or weighed if thela ter were not available. The cooking method 
was also described. In the end, during the visit session,  a dietitian went through the record with 
patients/parents to clarify details. 
Hematic parameters of antioxidant status: selenium, ascorbic acid, retinol and α-tocopherol in 
plasma samples, selenium dependent glutathione-peroxidase (GSH-PxSe), reduced glutathione 
(GSH) in red blood cells were considered as biochemical indexes of antioxidant status. 
Selenium (P-Se) was detected by SpectrAA 20 Graphite Furnace Atomic Absorption Spectroscope 
Varian (Varian Techtron Pty. Ltd., Australia); ascorbic acid was detected in plasma samples by 
HPLC (High Pressure Liquid Chromatography) according to Harapanalli (21). Retinol and α-
tocopherol were simultaneously evaluated by HPLC using a kit of Chromsystems Instruments and 
Chemical GmbH (Martinsried/Munich, Germany). Selenium-dependent-glutathione peroxidase 
activity in Red Blood Cells (RBC) was evaluated by spectrophotometrically (22).  Total and 
reduced glutathione was analyzed by HPLC after derivatization of hemolyzed samples with 
ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulphonate (SBD-F) (fluorescence detector Varian 
9070, 385 nm excitation/ 515 nm emission).  
Blood antioxidant were expressed as following: α-tocopherol (mg/l), ascorbic acid (mg/l), retinol 
(µg/l) and selenium (µg/l), reduced RBC-glutathione (GSH-µmol/gHb), selenium dependent 
glutathione peroxidase (GSH-PxSe-U/gHb). 
Study population was classified in clusters of optimal, suboptimal and deficient plasma vitamin E 
and C as described by Biesalski (23). For vitamin A we utilized the 25th and 90th percentile of 
retinol concentrations as cut-off values similar to th se proposed by Biesalski that deals with beta 
carotene. 
Oxidative stress markers. 
The presence of oxidative damage was assessed in plasma by determining the fluorescent adducts 
formed between lipid peroxidation-derived aldehydes and plasma lipids, also termed chromolipids. 
In particular, HNE-lipid adducts (355 nm excitation/460 nm emission) and MDA-lipid adducts (390 
nm excitation/460 nm emission) were evaluated. Preparation of samples and fluorimetric 
measurements were performed according to Biasi et al. (1995) (Kontron SFM 25 spectrofluorimeter, 
Kontron AG, Zurich, Switzerland). Data were expressed as Arbitrary Fluorescence Units 
(A.F.U.)/ml plasma and, as required, Arbitrary Fluorescence Units/mg plasma cholesterol. Plasma 
cholesterol was analyzed by an enzymatic colorimetric test (Olympus analyzer).         
Oxidative status was also estimated in RBC as a ratio of reduced glutathione and its oxidized form 
(GSSG). GSSG was calculated by HPLC as the differenc  between total and reduced glutathione.  
Statistical analysis 
Data are reported as median and range for continuous variables and number and percentage for 
categorical ones. 
Differences between groups were evaluated with the Mann-Whitney U test or the Kruskal-Wallis 
test, whilst correlation between continuous variables was checked with the Spearman correlation 
coefficient (ρs). All tests are two-sided and significant for p values less than 0.05. 
Data were analyzed with SPSS 17 (SPPS Inc., Chicago, IL). 
 
RESULTS 
General and clinical characteristics of the study population are reported in Table1.  
Red-ox status in CF pediatric patients  
Referring to the local reference range the majority of patients had normal concentrations of vitamins E, A, C 
and selenium (92.8%, 97.1%, 98.6% and 86.6%, respectively). Red blood cell concentrations of reduced 
glutathione and glutathione peroxidase (97% and 97% respectively) were also recorded (found normal). 
Interestingly, the GSH/GSSG ratio was low for 89.7% of patients. 
Chromolipids HNE-L and MDA-L, either as plasma levels or referred to mg of plasma cholesterol, were 
significantly higher than those of healthy people (local reference range - l.r.r.). Specifically, only 4.8% and 
1.6% of patients showed normal concentrations of HNE-L and MDA-L respectively.  
Evaluation of energy and nutrient intakes  
Analysis of three day food record revealed adequate energy and macronutrients intakes per kilogram of body 
weight and in percentage of total energy referring to Italian recommended intakes (LARN - Livelli di 
Assunzione Raccomandata di energia e Nutrienti) (24, though not as high as expected for CF patients 
(energy 81kcal/kg, lipids 33.7%, protein 16% and carbohydrates 52.3%).  Vitamin A and E intakes were 
aligned to the upper mentioned recommendations while vitamin C intake was slightly superior (78.4 vs. 40-
60 mg/day).   
Plasma antioxidant vitamins: relationship to clinical data and oxidative stress parameters. 
Applying the cut-off criteria suggested by Biesalsky (23), we obtained a picture that is quite different from 
the one obtained relying to the local reference range of normality for the vitamins plasma levels. A large 
group of patients (67.1%, 40.6% and 65.7%) showed  sub-optimal plasma levels of vitamin E, C and A 
respectively, running the risk of oxidative burden (Table 2). Because the sub-optimal levels are within e 
normal reference range, patients do not usually increase their supplementation doses. However, 21.5% and 
22.8% of patients had deficient  levels of vitamin  E and A despite oral vitamin supplementation.  
Age was the most relevant feature across the different clusters of patients: patients with optimal values are 
significantly younger than those with lower/deficit  vitamin levels (p<0.05 for vitamin E and C) (Table 2).  
Plasma oxidative stress markers HNE-L and MDA-L as well as the ratio with plasma cholesterol showed an 
increasing trend with lowering antioxidant vitamin concentrations. Interestingly, the difference is stati ically 
significant between patients with optimal versus suboptimal vitamin C levels  (p<0.05) for both chromolipids.  
There were no differences among groups for the clinical data.  
BMI z-score resulted significantly lower in patients with suboptimal vitamin C concentrations (p<0.05) 
compared to those with optimal ones (Table 2). 
Correlation of age with plasma antioxidant vitamins and oxidative stress markers in CF patients 
Plasma antioxidants were inversely correlated with age that exerts an independent significant effect in 
reducing vitamin E (ρs = -0.25, p = 0.034) and vitamin C (ρs = -0.27, p = 0.025). Although plasma vitamin 
A also claimed an inverse correlation with age, it was weaker and statistically significance was not reached 
(ρs = -0.06; p = 0.628). Plasma chromolipids increased significantly with age ( MDA-L/cholesterol ρs = 0.36, 
p= 0.003; HNE-L/cholesterolρs = 0.33, p= 0.004) (Fig.1). Aging accounted for 10% (MDA-L) and 12% 
(HNE-L) of increase in plasma chromolipids.  
Do antioxidant vitamin plasma levels correlate with oxidative status? 
Our data evidenced an inverse relation between plasma concentrations of both chromolipids and those of 
antioxidant vitamins (Fig. 2). In particular, vitamin C showed a significant inverse correlation with plasma 
chromolipids (ρs = -0.30, p = 0.018 for MDA-L/cholesterol; ρs = -0.36, p=0.004 for HNE-L/cholesterol).  
Effect of pancreatic insufficiency on oxidative stress markers 
Patients with or without PI showed similar plasma vit mins and GSH/GSSG ratio in their plasma. Again, 
plasma chromolipids were significantly higher in patients with PI compared to non-PI ones despite the 
vitamin supplementation compliant with international recommendations. A clear graphical description of the 
differences between the two groups is shown in Figure 3.  
Discussion 
Our data revealed that the majority of our CF patients showed elevated oxidative stress markers even 
in stable clinical conditions and with plasma antioxidants within the normal range. Aging led to a 
progressive increase of plasma oxidative stress markers in contrast with plasma antioxidant 
vitamins, whose availability decreased steadily. A similar inverse correlation was evidenced 
between plasma vitamins and oxidative stress markers with interesting and consistent results on 
vitamin C. Patients with pancreatic insufficiency, although well controlled, showed higher oxidative 
stress markers without significant differences in plasma vitamins. These data suggest the necessity 
of a careful definition of vitamin needs in CF patients preferably on an individual basis considering 
oxidative status.  
The poor antioxidant status in CF patients versus healt y subjects has been widely demonstrated 
(1,2,3). Plasma liposoluble vitamins are usually determined once a year and deficient patients are 
supplemented, compliant to recommendations, in order to comply with the normality range (25,26). 
Our data evidenced adequate plasma levels of exogenous and endogenous antioxidants and dietetic 
intakes of antioxidant vitamins in almost all patien s. Huang et al. have also documented that, with 
typical supplementation, very few children had low serum vitamin E status suggesting the necessity 
of dose and response studies in CF patients (7). Vitamin status is now considered more broadly, in 
relation to specific health outcomes. When defining the adequacy of vitamin levels as the ones 
within the normality range, we found some inconsistency: 40.6% of patients with suboptimal 
vitamin C were not detected by the reference range; with regards to the local reference range we 
detected 7.2% of patients with deficient vitamin E versus 21.5% indicated by the “new” 
classification (23). All of these patients showed significantly higher plasma chromolipids than those 
with optimal levels (Table 2). The lower level of our local reference range for α-tocopherol 
corresponds to the 5th percentile of NHANES III (25), the same utilized by Huang as the lower cut-
off value for vitamin E (7). Consistently with other studies patients with optimal vitamin E status 
were significantly younger and showed lower MDA-L/cholesterol (3). We can assume that higher 
levels of Vitamin E (12.9-18.9 mg/l) provide better protection against lipid peroxidation. None of 
our patients had deficient vitamin C taking no or low-dose vitamin supplementation as 
multivitamins (Table 2). Vitamin C levels decreased with age and MDA-L/cholesterol and HNE-
L/cholesterol increased with reducing plasma vitamin as documented by previous studies (2,3,26). 
Reduced BMI z-score in patients with suboptimal versus optimal vitamin C may be, at least in part, 
attributed to the higher oxidative stress (Table 2). Other studies have demonstrated the role of 
ascorbic acid as a potent antioxidant (27). It has been suggested to play a key role in controlling 
CFTR activity modifying its red-ox state (28). There are no recommendations for vitamin C 
supplementation in CF patients except for subjects with an unbalanced diet (9) or general indication 
of a standard age-appropriate dose of multivitamins (10) and our data confirmed the importance of 
vitamin C monitoring and supplementation.  
There were not significant differences in age, BMI z-score, number of exacerbations/year and FEV1 
between groups of patients with optimal versus suboptimal or deficient vitamin A (Table 2). 
We have not observed a significant reduction of vitam n A with age (ρs =-0.06, p=0.628) in contrast 
with Maqbool et al. (29). Mean serum retinol in that study was much higher than in ours (800µg/l) 
and 58% of patients had serum retinol above the NHAES reference range.  
Our data failed to confirm a correlation between chromolipids and plasma retinol in our CF patients 
(Fig.2) as identified in other studies. Wood documented an inverse correlation between and 8-iso-
PGF2α and β-carotene (2).  
8-iso-PGF2α has been considered a good method to measure lipid peroxidation. During this process 
a further chain cleavage yields several aldehydes, among them MDA and HNE. These aldehydes 
are highly reactive, thus the detection of their adducts to macromolecules, i.e. chromolipids, can 
provide more reliable data than other analytical methods on the extent of oxidative damage.   
Consistently with other studies (3,5) our data showed a strong positive correlation of chromolipids 
with age (Fig.1). An overconsumption of antioxidants was also documented as a consequence of 
increased oxidative stress with age. We showed that higher vitamin E and C provided a reduction in 
plasma chromolipids (Fig.2). It has been demonstrated that high doses of fat soluble vitamins 
carries on the risk of toxicity, whereas the supplementation of vitamin C does not show any 
important side effects except for very high dosages (30).  
Patients with pancreatic insufficiency showed higher plasma chromolipids (Fig.3). Interestingly, the 
effect persisted even when controlled for plasma vit min A, E and C. It may not be fully explained 
with lipid malabsorption because it was well controlled by PERT and vitamin C is not involved. In 
fact we couldn’t evidence any difference in fat soluble vitamins in patients with or without 
pancreatic insufficiency. We think it could be ascribed to the higher rate of infections (0.64 vs 1.97, 
p=0.010) and to the genotype (82% ∆F508) of the PI patients. Our data suggest that 
supplementation strategies might consider these oxidative stress markers in addition to the plasma 
antioxidant vitamins, at least in patients with pancreatic insufficiency. However, this statement 
needs to be validated through further research, with a focus in identifying reliable markers of 
oxidative status to be correlated to the clinical st te.  
The principal limitation of our study is the limited number of oxidative stress markers considered. 
In particular, exhaled breath or sputum analysis were not evaluated. Blood antioxidants reflect the 
overall capacity of the organism to afford oxidative stress burden. Moreover, the airways 
experienced higher oxidative stress because of the def ctive glutathione transport through the 
epithelial cells for the CFTR mutation. We assume that antioxidant vitamins exert different roles on 
plasma and airways. However, completing data of the present study with further studies focused on 
antioxidants and oxidative damage markers specific for the airways may be useful to better 
understand the complex redox unbalance in CF. 
 
CONCLUSIONS  
Oxidative stress characterizes CF patients from the pediatric age and it progressively increases over the years. 
Reducing its harmful impact is an important clinical goal. This may be achieved by the optimization of 
antioxidant vitamin status, and reference ranges for healthy people provide incomplete information. The 
good management of red-ox balance in CF patients requires reference ranges elaborated on the basis of data 
from adequate control population. Aldehyde-lipid adducts may be used to characterize oxidative status and 
guide antioxidant supplementation on an individual basis. Definition of optimal levels of fat soluble vitamins 
require further studies, while obtaining higher plasm  levels of vitamin C seems useful and feasible. Patients 
with pancreatic insufficiency need a careful monitoring of their red-ox balance because at risk of excessive 
oxidative stress.      
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